Department of Dermatology, Schleswig-Holstein University Hospital, Campus Kiel, Germany.
Anticancer Res. 2010 May;30(5):1799-805.
Serum S100B and LDH, as well as the status of the sentinel node, have been reported as prognostic markers in melanoma patients. The purpose of this study was to determine the value of serum S-100B and LDH in melanoma patients prior to sentinel lymph node dissection (SLND) with respect to the clinical outcome.
Serum S100B and LDH were measured prior to SLND in 259 melanoma patients between 2000 and 2006. Upper institutional limits were 0.12 microg/l for S100B and 240U/l for LDH.
The median follow-up time was 27.1 months. The median S-100B value for SN-negative and SN-positive patients was 0.06 microg/l and 0.05 microg/l, respectively (p=0.291). Similarly for LDH, the values were 171.5 U/l and 166.5 U/l, respectively (p=0.763). Neither of the proposed markers were a statistically significant prognostic parameter for disease-free survival (DFS), distant metastasis-free survival (DMFS) and overall survival (OS).
In the present study neither serum S100B nor LDH prior to SLND were useful in predicting the histopathological status of the sentinel node. None of them correlated with DFS, DMFS or OS.
血清 S100B 和 LDH 以及前哨淋巴结的状态已被报道为黑色素瘤患者的预后标志物。本研究的目的是确定在进行前哨淋巴结活检（SLND）之前，血清 S100B 和 LDH 对黑色素瘤患者的临床结局的价值。
在 2000 年至 2006 年间，对 259 名黑色素瘤患者在 SLND 前测量了血清 S100B 和 LDH。上机构上限分别为 S100B 为 0.12 微克/升和 LDH 为 240U/L。
中位随访时间为 27.1 个月。SN 阴性和 SN 阳性患者的 S-100B 中位数分别为 0.06 微克/升和 0.05 微克/升（p=0.291）。同样对于 LDH，值分别为 171.5 U/l 和 166.5 U/l（p=0.763）。在预测无病生存率（DFS）、远处转移无复发生存率（DMFS）和总生存率（OS）方面，这两种标志物都不是统计学上显著的预后参数。
在本研究中，SLND 前的血清 S100B 和 LDH 均不能用于预测前哨淋巴结的组织病理学状态。它们均与 DFS、DMFS 或 OS 无关。
Zotero 插件